MedTrace Logo

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

NCT07070440 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-08-29

No results posted yet for this study

Summary

This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

DZD6008

DZD6008 was administered orally at 40/60/90 mg QD.

DRUG

Pemetrexed

Pemetrexed 500 mg/m2, every 3 weeks, intravenous infusion.

DRUG

Carboplatin

Carboplatin AUC 5 mg/mL/min, every 3 weeks, intravenous infusion.

DRUG

Docetaxel

Docetaxel 75 mg/m2, every 3 weeks, intravenous infusion.

Sponsors & Collaborators

  • Dizal Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Lu · Shanghai Chest Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-16
Primary Completion
2027-06-30
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07070440 on ClinicalTrials.gov